Source link : https://www.newshealth.biz/health-news/gotistobart-trial-for-nsclc-on-partial-clinical-hold/
The US Food and Drug Administration (FDA) has placed a partial clinical hold on the phase 3 PRESERVE-003 trial of BNT316/ONC-392 (gotistobart, BioNTech and OncoC4) for non–small cell lung cancer (NSCLC) due to varying results in patients with squamous and non-squamous NSCLC. Gotistobart is a next-generation anti-cytotoxic T-lymphocyte-associated protein 4 antibody candidate in late-stage clinical […]
Author : News Health
Publish date : 2024-10-23 09:51:07
Copyright for syndicated content belongs to the linked Source.